(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 September 2021 (16.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/180952 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 25/22* (2006.01)
C07D 471/04 (2006.01) *A61P 29/00* (2006.01)
C07D 491/04 (2006.01) *A61K 31/519* (2006.01)
A61P 25/08 (2006.01)

(21) International Application Number:
PCT/EP2021/056393

(22) International Filing Date:
12 March 2021 (12.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/989,104 13 March 2020 (13.03.2020) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors: **JARVIS, Rebecca, Elizabeth**; MedImmune Limited Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **BÜRLI, Roland, Werner**; MedImmune Limited Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(74) Agent: **ASTRAZENECA**; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: FUSED PYRIMIDINE COMPOUNDS AS KCC2



(I)

(57) Abstract: The invention concerns compounds of Formula (I): (I) or pharmaceutically acceptable salts thereof, wherein R^1, R^2, R^7 and ring A have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KCC2 mediated diseases.

WO 2021/180952 A1